Semax and selank for ADHD and focus: what the science says

What did @alexfraysse_coaching actually say?

The creator pitched semax, which they called "C-Max," as a medication-free option for people who "struggle focusing" or have ADHD. The core claims: semax increases dopamine signaling without the stimulatory effect of amphetamines, boosts BDNF, enhances neuroplasticity, and in their words, "makes you smarter." It can be used as a nasal spray or subcutaneous injection. That's a lot of ground to cover in thirty seconds, and not all of it lands the same way.

Worth noting upfront: the creator mispronounced or misspelled the name as "C-Max" throughout, and the word "ampaclements" appears to be a garbled reference to amphetamines. These aren't just cosmetic errors. If you're advising people with ADHD to consider an unregulated peptide instead of medication, precision matters.

Does the science back this up?

Partially, but the evidence is thinner than the confident delivery suggests. Most semax research comes from Russian studies, often with small sample sizes, and it hasn't been evaluated by the FDA. The dopamine and BDNF claims have some preclinical support, but human trial data is limited.

Semax is a synthetic heptapeptide derived from ACTH(4-10) developed in Russia, where it holds official drug status for stroke and cognitive impairment. Animal studies have shown it can increase BDNF expression in the hippocampus (Dolotov et al., 2006, Journal of Neurochemistry), and rodent models suggest it modulates dopaminergic and serotonergic pathways. One small human study by Kaplan et al. (2017, CNS Drug Reviews) noted cognitive effects in stroke patients, but that population is very different from healthy adults or people with ADHD. There are no published randomized controlled trials in ADHD populations. The BDNF-to-neuroplasticity-to-focus chain the creator describes is scientifically plausible as a hypothesis, not a demonstrated outcome in humans seeking productivity gains.

What did they get wrong (or right)?

They got the BDNF mechanism directionally right, but oversold it badly. Saying semax "makes you smarter" is not a scientific claim. It's marketing language dressed up in biology vocabulary.

The dopamine claim deserves more scrutiny. The creator says you get "more dopamine without the same stimulatory effect" as amphetamines. The mechanism here is not well-characterized in humans. Amphetamines work primarily by forcing dopamine release and blocking reuptake. Semax, if it affects dopamine at all in humans, likely does so indirectly through BDNF or ACTH-related pathways. Saying it gives you more dopamine without stimulation implies a clean comparison that the evidence doesn't support. It also implies equivalency in outcome with stimulant medications, which is a significant overreach.

What they got right: semax does appear to have a real, if modest, evidence base for cognitive effects in preclinical models. It is used as a nasal spray in countries where it's approved. These aren't invented claims. But presenting a Russian-approved neuropeptide with no ADHD trial data as something that "may be the solution" for ADHD is a different conversation entirely.

What should you actually know?

Semax is not FDA-approved for any condition. In the United States, it exists in a gray zone, sometimes compounded by specialty pharmacies, sometimes sold online with questionable quality controls. That matters when you're considering nasal administration or injections.

ADHD is a legitimate neurodevelopmental condition with treatment protocols backed by decades of research. The medications the creator is steering people away from, stimulants and non-stimulants alike, have robust safety and efficacy data in controlled trials. Semax does not. That asymmetry isn't a reason to dismiss semax entirely, but it is a reason to be skeptical of anyone framing it as a straightforward substitute.

If you're interested in semax, the honest conversation involves a clinician who understands its mechanism, the sourcing question, and why you're considering it in the first place. A thirty-second TikTok with the peptide's name mispronounced is not that conversation. BDNF research is genuinely interesting territory, but interesting research is not the same as a clinical recommendation.